Skip to content
  • RESEARCH
  • PUBLICATIONS
  • TEAM
  • LAB NEWS
  • CONTACT
  • RESEARCH
  • PUBLICATIONS
  • TEAM
  • LAB NEWS
  • CONTACT

© 2019

Colorectal cancer models for novel drug discovery.

Golovko D, Kedrin D, Yilmaz ÖH, Roper J*.

Colorectal cancer models for novel drug discovery.

Expert Opin Drug Discov. 2015;10(11):1217–29. PMID: 26295972, PMCID: 4872297

2015

Tags
2015

Post navigation

Previous post Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR.

Post navigation

Next post Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH.
Recent Posts
  • Weight Loss and/or Sulindac Mitigate Obesity-associated Transcriptome, Microbiome, and Protumor Effects in a Murine Model of Colon Cancer
  • CAUSE, EPIDEMIOLOGY, AND HISTOLOGY OF POLYPS AND PATHWAYS TO COLORECTAL CANCER
  • SPECTROSCOPIC OPTICAL COHERENCE TOMOGRAPHY FOR CLASSIFICATION OF COLORECTAL CANCER IN A MOUSE MODEL
  • METABOLISM AND COLORECTAL CANCER
  • MIRROR MIRROR ON THE WALL, WHO IS THE FITTEST OF THEM ALL: A NOVEL PREDICTION MODEL FOR POSTOPERATIVE HEPATIC DECOMPENSATION IN PATIENTS WITH CIRRHOSIS
Archives
  • April 2023
  • January 2022
  • February 2020
  • January 2020
Categories
  • Publications
Meta
  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org
© 2025 Roper Labs. Created for free using WordPress and Colibri